Rep. Kevin Hern sold DexCom (DXCM)
Rep. Kevin Hern (R-OK-1) · $50K–$100K · traded Dec 31, 2024
- Transaction
- Sold
- Amount
- $50K–$100K
- Owner
- Joint
- Traded
- Dec 31, 2024
- Disclosed
- Jan 15, 2025
- Days to disclose
- 15
- Asset type
- Stock
- As filed
- DexCom, Inc. - Common Stock
- Industry
- Medical - Devices · Healthcare
Other trades in this filing
- Jan 15, 2025$15K–$50K
Sold The Estée Lauder Companies EL
$15K–$50K · Traded Dec 31, 2024 · disclosed Jan 15, 2025 · Joint
- Jan 15, 2025$50K–$100K
- Jan 15, 2025$100K–$250K
$100K–$250K · Traded Dec 31, 2024 · disclosed Jan 15, 2025 · Joint
- Jan 15, 2025$50K–$100K
$50K–$100K · Traded Dec 31, 2024 · disclosed Jan 15, 2025 · Joint
Got $4K from the company’s PAC - Jan 15, 2025$250K–$500K
Sold (partial) Devon Energy DVN
$250K–$500K · Traded Dec 31, 2024 · disclosed Jan 15, 2025 · Joint
- Jan 15, 2025$1K–$15K
$1K–$15K · Traded Dec 12, 2024 · disclosed Jan 15, 2025 · Joint
Got $20K from the company’s PAC - Jan 15, 2025$1K–$15K
Bought Exxonmobil Holdings XOM
$1K–$15K · Traded Dec 10, 2024 · disclosed Jan 15, 2025 · Joint
- Jan 15, 2025$500K–$1M
$500K–$1M · Traded Dec 3, 2024 · disclosed Jan 15, 2025 · Joint
Recent Congress trades in DXCM
- May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- May 10, 2026$100K–$250K
Sen. Tina Smith (D-MN)
$100K–$250K · Traded May 7, 2026 · disclosed May 10, 2026 · Spouse
- May 10, 2026$100K–$250K
Sen. Tina Smith (D-MN)
$100K–$250K · Traded Apr 29, 2026 · disclosed May 10, 2026 · Spouse
- Feb 15, 2026$1K–$15K
Sen. John Boozman (R-AR)
$1K–$15K · Traded Jan 26, 2026 · disclosed Feb 15, 2026 · Joint
- Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- Jun 9, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded May 15, 2025 · disclosed Jun 9, 2025
Company context for DXCM
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
DXCM: third_quarter 2026 lobbying report
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Public: Oct 20, 2026, 1:07 PM EDTOriginal source ↗DXCM: third_quarter 2026 lobbying report
Issues related to global supply chains Issues related to the Administration's Executive Orders CGM Coverage policy Issues related to sterilization of medical devices Issues related to medical device electronic labeling H.R.1539, Medical Device Electronic Labeling Act Issues related to artificial intelligence and other machine learning advances in healthcare Issues related to advances in diabetes technology Issues related to CY 2026 rulemaking CGM Coverage policies Issues related to breakthrough technology
Public: Oct 20, 2026, 11:00 AM EDTOriginal source ↗DXCM: third_quarter 2026 lobbying report
Issues related to coverage and reimbursement for continuous glucose monitors. Issues related to coverage and reimbursement for continuous glucose monitors.
Public: Oct 20, 2026, 10:03 AM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.